Physician profile
Sarah E Cox
NPI 1598497489
$3,503.44
in general payments reported to CMS, 2019-2025
30 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $243 · 2023: $825 · 2024: $901 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,228 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,227.78 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $616.68 | 2023-2025 | |
| Abbvie INC. | $545.06 | 2023-2025 | |
| Novo Nordisk INC | $482.09 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $188.88 | 2022-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $169.49 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $161.78 | 2024-2025 | Breztri, Airsupra |
| Amgen INC. | $149.95 | 2023-2025 | Evenity, Prolia, Otezla |
| Dexcom, INC. | $140.10 | 2024-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $133.73 | 2023-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $115.96 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $103.55 | 2023-2024 | Austedo Xr, Austedo |
| Vertex Pharmaceuticals Incorporated | $87.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.18 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.93 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $78.64 | 2024-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $50.85 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Phathom Pharmaceuticals, INC. | $47.61 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.43 | 2024-2025 | Jardiance |
| Abbott Laboratories | $35.59 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $34.29 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $33.70 | 2022 | |
| Kyowa Kirin, INC. | $19.58 | 2025 | |
| Sunovion Pharmaceuticals INC. | $17.98 | 2022 | |
| Averitas Pharma INC. | $15.67 | 2024 | Qutenza |
| Idorsia Pharmaceuticals US INC | $14.44 | 2022 | |
| Exact Sciences Corporation | $13.68 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.67 | 2023 | Xifaxan |
| Impel Pharmaceuticals INC. | $13.44 | 2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $12.21 | 2023 | Gemtesa |
| Corium, LLC | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.